Suppr超能文献

口服荧光素钠可改善增殖性糖尿病视网膜病变玻璃体切除术中透明玻璃体的可视化。

Oral sodium fluorescein to improve visualization of clear vitreous during vitrectomy for proliferative diabetic retinopathy.

作者信息

Yao Yi, Wang Zhi-Jun, Wei Shi-Hui, Huang Yi-Fei, Zhang Mao-Nian

机构信息

Department of Ophthalmology, The General Hospital of Chinese PLA, Beijing, China.

出版信息

Clin Exp Ophthalmol. 2007 Dec;35(9):824-7. doi: 10.1111/j.1442-9071.2007.01610.x.

Abstract

PURPOSE

To evaluate the efficacy and safety of orally administered sodium fluorescein to stain the clear vitreous before vitrectomy for proliferative diabetic retinopathy (PDR).

METHODS

Twenty-two consecutive eyes of 20 patients with PDR and five eyes of five patients with proliferative vitreoretinopathy (PVR) were included. The average patient age was 52 years (range 46-58). Closed pars plana vitrectomy, proliferative membrane peeling and endolaser photocoagulation were performed. Vitreous and blood samples were collected to measure sodium fluorescein concentrations by high pressure liquefied chromatography.

RESULTS

The degree of staining of the clear vitreous was evaluated by colour photographs, videos and the concentration of sodium fluorescein in the vitreous and blood samples. The clear vitreous in all 22 eyes with PDR ranged from slightly to markedly green, but the clear vitreous in five eyes with PVR was not stained with sodium fluorescein. The sodium fluorescein concentration in the vitreous samples ranged from 122 to 282.0 ng/mL and from 64 to 74 ng/mL in the blood samples in patients with diabetes and PVR. No urticaria, nausea or other side-effects developed.

CONCLUSION

The clear vitreous can be stained markedly green by sodium fluorescein administered 12-16 h before surgery. Surgeons can easily differentiate residual clear vitreous. The stained vitreous may be made more visible by photocoagulation. This method is also helpful in teaching surgical procedures, and fewer side-effects compared with intravenous and intravitreal fluorescein and intravitreal triamcinolone.

摘要

目的

评估口服荧光素钠在增殖性糖尿病视网膜病变(PDR)玻璃体切除术前对透明玻璃体进行染色的有效性和安全性。

方法

纳入20例PDR患者的22只连续眼以及5例增殖性玻璃体视网膜病变(PVR)患者的5只眼。患者平均年龄为52岁(范围46 - 58岁)。进行了闭合式平坦部玻璃体切除术、增殖膜剥除术和眼内激光光凝术。收集玻璃体和血液样本,通过高压液相色谱法测量荧光素钠浓度。

结果

通过彩色照片、视频以及玻璃体和血液样本中荧光素钠的浓度评估透明玻璃体的染色程度。所有22只PDR眼的透明玻璃体呈现从轻微到明显的绿色,但5只PVR眼的透明玻璃体未被荧光素钠染色。糖尿病和PVR患者玻璃体样本中荧光素钠浓度范围为122至282.0 ng/mL,血液样本中为64至74 ng/mL。未出现荨麻疹、恶心或其他副作用。

结论

术前12 - 16小时给予荧光素钠可使透明玻璃体明显染成绿色。手术医生能够轻松区分残留的透明玻璃体。通过光凝可使染色的玻璃体更易于观察。该方法在手术操作教学中也有帮助,且与静脉注射和玻璃体内注射荧光素以及玻璃体内注射曲安奈德相比副作用更少。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验